

Phosphatidylinositol 4,5 Bisphosphate Market Size Share And Key Players – Pipeline Review, H2 2017

PUNE, MAHARASHTRA, INDIA, February 21, 2018 /EINPresswire.com/ --

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Phosphatidylinositol 4,5 Bisphosphate - Pipeline Review, H2 2017”

Phosphatidylinositol 4,5 Bisphosphate

Overview

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - The phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha also called p110 α is a protein encoded by the PIK3CA gene.

It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin receptor substrate (IRS) proteins. It is essential in endothelial cell migration during vascular development through VEGFA signaling. It is required for lymphatic vasculature development.

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/629561-phosphatidylinositol-4-5-bisphosphate-protein-kinase-pik3>

Top Companies mentioned

AstraZeneca Plc

Bayer AG

Curis Inc

Eli Lilly and Co

Genentech Inc



WISE GUY
REPORTS

AKASH ANAND
ASST.MANAGER - BUSINESS DEVELOPMENT

sales@wiseguyreports.com
Ph: +1-646-843-9312 (US) Ph: +44 208 133 9349 (UK)

<https://www.linkedin.com/company/4828928>
<http://twitter.com/WiseGuyReports>
<http://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Phosphatidylinositol 4,5 Bisphosphate

GlaxoSmithKline Plc

Millennium Pharmaceuticals Inc

Novartis AG

Onconova Therapeutics Inc

PIQR Therapeutics AG

Phosphatidylinositol 4,5 Bisphosphate Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Phosphatidylinositol 4,5 Bisphosphate - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Phosphatidylinositol 4,5 Bisphosphate , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 19 molecules.

Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 7 respectively.

Phosphatidylinositol 4,5 Bisphosphate pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Phosphatidylinositol 4,5 Bisphosphate - Competitive Analysis

Key players are making innovative developments in Phosphatidylinositol 4,5 Bisphosphate industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Phosphatidylinositol 4,5 Bisphosphate.

The pipeline guide reviews pipeline therapeutics for Phosphatidylinositol 4,5 Bisphosphate by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Phosphatidylinositol 4,5 Bisphosphate therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Phosphatidylinositol 4,5 Bisphosphate therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Phosphatidylinositol 4,5 Bisphosphate.

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/629561-phosphatidylinositol-4-5-bisphosphate-protein-kinase-pik3>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

[email us here](mailto:sales@wiseguyreports.com)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.